T1	Participants 85 132	very platinum-sensitive ovarian cancer patients
T2	Participants 234 342	patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial
T3	Participants 414 526	women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies.
T4	Participants 369 382	international
T5	Participants 875 959	A total of 259 very platinum-sensitive patients were included (n=131, CD; n=128, CP)
T6	Participants 1819 1860	patients with very platinum-sensitive ROC
